Fresenius Medical Care

Today, Fresenius Medical Care announced Shervin Korangy will become Chief Executive Officer and Chair of the Management Board, effective October 12, 2026. The Supervisory Board unanimously appointed him to succeed Helen Giza, who has served as CEO and Chair of the Management Board for four years, following three years as CFO. “The Supervisory Board is grateful to Helen for her leadership and commitment over the past seven years. Under her leadership, the Company successfully addressed key operational and financial priorities and became more efficient, profitable and resilient,” said Michael Sen, Chairman of the Fresenius Medical Care Supervisory Board. “Fresenius Medical Care has reached an important strategic inflection point. The transformation of recent years has largely achieved its objectives, and the next phase of growth will benefit from a different leadership profile,” said Mr. Sen. “Shervin is the natural choice to lead FME forward. Through our close work with him on the Supervisory Board, we have seen his vision, judgement and rigor first-hand. He combines broad executive experience and an external perspective with a strong understanding of FME. His healthcare leadership, operational transformation and capital allocation expertise will support long-term profitable growth and value creation.“ Read the press release here: https://lnkd.in/es2nmqi3 #ProudToBeFME

FX CorAL® dialysers support better haemodialysis by combining clinical performance with improved haemocompatibility. It reduces inflammation and helps protect those living with kidney disease over time. Swipe to see what sets FX CorAL® apart.

Better outcomes start with better biocompatibility. FX CorAL® dialysers combine advanced clinical performance with a high level of haemocompatibility. It’s designed to reduce inflammation and protect those living with kidney disease from dialysis-related complications. ✅ Lower complement activaton and lower platelet loss ✅ Improved clearance of middle molecules ✅ Greater albumin retention ✅ Lower leukocyte activation Combining clinical performance with haemocompatibility, FX CorAL® belongs in dialysis care centred around those living with kidney disease.

Protecting against venous needle dislodgement (VND) is critical in haemodialysis care. Our VenAcc solution is an external wetness detector designed to identify blood loss at the venous access site. When detected, an alarm is triggered to stop the blood pump, supporting early intervention and reducing the risk of serious complications. VenAcc provides: ✅ Rapid detection of blood loss ✅ Improved monitoring may provide a diminished risk of blood loss ✅ Early detection and optimised monitoring of the venous path potentially contributes to improved safety Enhance safety with proactive VND management.

Protecting against needle dislodgement is critical in haemodialysis care. VenAcc detects blood loss at the venous access site and triggers an alarm to stop the blood pump, supporting early intervention. Swipe to learn more.

The Power of Care lives in the moments that matter most. It is found in the trust our nurses and care teams build, the reassurance they provide when it’s needed most, and the expertise they bring to every patient, every moment, and every day. Following on U.S National Nurses Week and #InternationalNursesDay, we continue to celebrate how these individual "moments of care" collectively bring our mission to life. Whether supporting patients in-center or through home therapies, our teams don’t just deliver care, they provide comfort and safety. 💙 We take great pride in the nurses and care teams whose expertise and dedication make this impact possible, every single day. Watch how these moments of care transcend borders, from Ireland to the U.S. 👉 Discover the full story here: https://lnkd.in/eTFej9uN #IND2026 #NationalNursesWeek #INDatFME #ProudToBeFME